Dr. Martens (LON:DOCS – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Berenberg Bank in a report issued on Friday, October 9th, Marketbeat.com reports. They currently have a GBX 110 target price on the stock. Berenberg Bank’s price target suggests a potential upside of 59.88% from the company’s current price.
Dr. Martens Stock Up 0.9%
Shares of DOCS traded up GBX 0.60 during mid-day trading on Friday, hitting GBX 68.80. 1,484,075 shares of the company’s stock were exchanged, compared to its average volume of 6,314,625. Dr. Martens has a 52 week low of GBX 59.15 and a 52 week high of GBX 97.05. The company has a market cap of £658.53 million, a PE ratio of 28.67, a P/E/G ratio of 6.40 and a beta of 0.26. The company has a debt-to-equity ratio of 108.85, a current ratio of 2.61 and a quick ratio of 1.13. The company has a 50-day simple moving average of GBX 73.35 and a 200 day simple moving average of GBX 71.05.
Insider Buying and Selling at Dr. Martens
In other news, insider Ije Nwokori sold 209,160 shares of the business’s stock in a transaction that occurred on Friday, October 16th. The shares were sold at an average price of GBX 69, for a total value of £144,320.40. Insiders have acquired a total of 810 shares of company stock valued at $60,112 over the last quarter. Insiders own 2.94% of the company’s stock.
About Dr. Martens
Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot – named after the date it was produced – rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, “Docs” or “DM’s” were later adopted by musicians and subcultural pioneers who took them from the street to the global stage.
Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.
Further Reading
- Five stocks we like better than Dr. Martens
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Dr. Martens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Martens and related companies with MarketBeat.com's FREE daily email newsletter.
